Daniel C. Martin
2020
In 2020, Daniel C. Martin earned a total compensation of $2.6M as Chief Commercial Officer at Deciphera Pharmaceuticals, a 27% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $247,141 |
|---|---|
| Option Awards | $1,546,335 |
| Salary | $436,800 |
| Stock Awards | $386,285 |
| Other | $23,882 |
| Total | $2,640,443 |
Martin received $1.5M in option awards, accounting for 59% of the total pay in 2020.
Martin also received $247.1K in non-equity incentive plan, $436.8K in salary, $386.3K in stock awards and $23.9K in other compensation.
Rankings
In 2020, Daniel C. Martin's compensation ranked 4,340th out of 13,090 executives tracked by ExecPay. In other words, Martin earned more than 66.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,340 out of 13,090 | 67th |
Division Manufacturing | 1,762 out of 5,621 | 69th |
Major group Chemicals And Allied Products | 689 out of 2,254 | 69th |
Industry group Drugs | 590 out of 1,954 | 70th |
Industry Pharmaceutical Preparations | 450 out of 1,459 | 69th |
Source: SEC filing on April 26, 2022.
Martin's colleagues
We found four more compensation records of executives who worked with Daniel C. Martin at Deciphera Pharmaceuticals in 2020.